Recombinant Human Semaphorin-3F (SEMA3F) Protein (His-Myc)

Beta LifeScience SKU/CAT #: BLC-02546P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Semaphorin-3F (SEMA3F) Protein (His-Myc)

Beta LifeScience SKU/CAT #: BLC-02546P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Semaphorin-3F (SEMA3F) Protein (His-Myc) is produced by our Mammalian cell expression system. This is a full length protein.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb Q13275
Target Symbol SEMA3F
Synonyms SEM3F_HUMAN; sema domain immunoglobulin domain Ig short basic domain secreted 3F; sema domain immunoglobulin domain Ig short basic domain secreted semaphorin 3F; Sema III/F; Sema IV; SEMA-IV; SEMA3F; SEMA4; SemaIII/F; SemaIV; SEMAK; Semaphorin IV; Semaphorin-3F; Semaphorin3F; SemaphorinIV
Species Homo sapiens (Human)
Expression System Mammalian cell
Tag N-6His-Myc
Target Protein Sequence SFPTQDHLPATPRVRLSFKELKATGTAHFFNFLLNTTDYRILLKDEDHDRMYVGSKDYVLSLDLHDINREPLIIHWAASPQRIEECVLSGKDVNGECGNFVRLIQPWNRTHLYVCGTGAYNPMCTYVNRGRRAQATPWTQTQAVRGRGSRATDGALRPMPTAPRQDYIFYLEPERLESGKGKCPYDPKLDTASALINEELYAGVYIDFMGTDAAIFRTLGKQTAMRTDQYNSRWLNDPSFIHAELIPDSAERNDDKLYFFFRERSAEAPQSPAVYARIGRICLNDDGGHCCLVNKWSTFLKARLVCSVPGEDGIETHFDELQDVFVQQTQDVRNPVIYAVFTSSGSVFRGSAVCVYSMADIRMVFNGPFAHKEGPNYQWMPFSGKMPYPRPGTCPGGTFTPSMKSTKDYPDEVINFMRSHPLMYQAVYPLQRRPLVVRTGAPYRLTTIAVDQVDAADGRYEVLFLGTDRGTVQKVIVLPKDDQELEELMLEEVEVFKDPAPVKTMTISSKRQQLYVASAVGVTHLSLHRCQAYGAACADCCLARDPYCAWDGQACSRYTASSKRRSRRQDVRHGNPIRQCRGFNSNANKNAVESVQYGVAGSAAFLECQPRSPQATVKWLFQRDPGDRRREIRAEDRFLRTEQGLLLRALQLSDRGLYSCTATENNFKHVVTRVQLHVLGRDAVHAALFPPLSMSAPPPPGAGPPTPPYQELAQLLAQPEVGLIHQYCQGYWRHVPPSPREAPGAPRSPEPQDQKKPRNRRHHPPDT
Expression Range 19-785aa
Protein Length Full Length of Mature Protein
Mol. Weight 90.5kDa
Research Area Others
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function May play a role in cell motility and cell adhesion.
Subcellular Location Secreted.
Protein Families Semaphorin family
Database References
Tissue Specificity Expressed abundantly but differentially in a variety of neural and nonneural tissues. There is high expression in mammary gland, kidney, fetal brain, and lung and lower expression in heart and liver.

Gene Functions References

  1. SEMA3F plays a role as a tumor suppressor in Oral squamous cell carcinoma cell proliferation, migration and invasion. PMID: 29299034
  2. in situ hybridization analysis revealed that Sema 3C and Sema 3F are expressed at the RNA level in the endometriosis affected peritoneum PMID: 27558236
  3. Semaphorin 3F placenta tissue expression was significantly reduced in preeclampsia. In addition, semaphorin 3F level at delivery was significantly lower in serum, amniotic fluid and venous umbilical blood of preeclamptic patients compared with normal pregnant women. PMID: 28350837
  4. There is a positive association between the expression of AKAP12 and Semaphorin 3F in prostate cancer, suggesting that the activation of Semaphorin 3F by AKAP12 may be involved in prostate cancer progression and metastasis. PMID: 28698137
  5. Study demonstrates an anti-tumoral role of SEMA3F in ileal NETs. We thus suggest that SEMA3F and/or its cellular signaling pathway could represent a target for ileal NET therapy. PMID: 26447612
  6. SEMA3F was downregulated in colorectal cancer tissues as compared to matched adjacent non-tumor tissues PMID: 26722466
  7. A new SEMA3F transcript is expressed in all breast cell lines and breast cancer biopsies, and is translated into a new semaphorin 3F isoform. PMID: 26784191
  8. SEMA3F-NRP2 interactions inhibit intracellular PI-3K activity, mTORC2-dependent signaling, RhoA activity and cytoskeletal stress fiber formation. PMID: 26156437
  9. Data indicate that semaphorin 3F (SEMA3F) and its receptor neuropilin-2 (NRP2) are expressed in the thymus. PMID: 25068647
  10. SEMA3F functions as a suppressor of colorectal cancer metastasis by down-regulating the ASCL2-CXCR4 signaling axis. PMID: 25866254
  11. SEMA3F may represent an antilymphangiogenic metastasis suppressor gene widely lost during cancer progression, hence serving as a prognostic biomarker and an attractive target for therapeutic intervention to halt metastasis. PMID: 25952650
  12. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by SEMA3E and SEMA3F. PMID: 26086095
  13. Data suggest that SEMA3F C-terminal domain exhibits high-affinity binding of neuropilin-1 (NRP1; thus inhibiting binding of vascular endothelial growth factor A to NRP1); this interaction may be involved in anti-angiogenic activity of SEMA3F. PMID: 24079887
  14. A functional role for Semaphorin 3F in the outer retina where it acts as a vasorepulsive cue to maintain physiologic avascularity. PMID: 23603393
  15. This study demonstrated a marked loss of noradrenergic and sensory nerve fibers in polyp mucosa, which was associated with a strong increase of semaphorin 3F and 3A. PMID: 22093159
  16. It was concluded that hypoxia regulates VEGF and SE MA3F activities through transcriptional repression of their common receptor NRP2, providing a novel mechanism by which hypoxia induces tumor angiogenesis, growth and metastasis. PMID: 21610314
  17. Endogenous SEMA3F acts as a suppressor of the growth and metastasis of human colorectal cancer cells. PMID: 21349996
  18. SEMA3F, CLEC16A, LAMA3, and PCSK2 variants have roles in myocardial infarction in Japanese individuals PMID: 20036365
  19. semaphorin-3B and semaphorin-3F have roles in ovarian cancer PMID: 20124444
  20. Transient SEMA-3F gene transfection may inhibit the proliferation of Tca8113 cells. PMID: 18476556
  21. Metastatic tumor cells overexpress c-myc, leading to upregulation of Id2 expression; the aberrantly elevated amount of Id2 represses SEMA3F expression and, as a consequence, enhances the ability of tumor cells to migrate and invade. PMID: 20388805
  22. SEMA3F and VEGF have antagonistic actions affecting motility in primary tumor cell PMID: 12659673
  23. SEMA3F is a potent metastasis inhibitor that targets both tumor and stromal cells PMID: 15520858
  24. SEMA3F suppresses lung neoplasm progression in an experimental model PMID: 15967098
  25. Results suggest that p53 negatively regulates tumor vessel formation and cell growth via the SEMA3F-NRP2 pathway. PMID: 17308083
  26. combinations of sema3A and sema3F may be able to inhibit tumor angiogenesis more effectively than single semaphorins. PMID: 17569671
  27. Semaphorin 3F mRNA forms a G quartet-containing structure, which is recognized with high affinity and specificity by the RGG box domain of the fragile X mental retardation protein. PMID: 17693432
  28. ABL2/ARG is a novel mediator of SEMA3F-induced RhoA inactivation and collapsing activity. PMID: 18660502
  29. SEMA3F loss was associated with changes in cell signaling: increased phospho-AKT in normoxia and hypoxia-induced factor 1alpha protein. Exogenous addition of SEMA3F could modulate ZEB-1-induced angiogenesis in a chorioallantoic membrane assay. PMID: 19177200
  30. Semaphorin3F reverses Multicellular resistance by regulating alpha(v)beta3 PMID: 19657188
  31. These data indicate that polymorphisms in SEMA3F are associated with prostate cancer risk and poor prognosis in Hispanic and nonHispanic white men PMID: 19683737
  32. Soluble neuropilin-2Fc did not inhibit repulsion but increased the repellent effect of semaphorin 3F. PMID: 19790074
  33. Sema3F inhibits tumor development from MDA-MB-435 and MDA-MB-231 and but not MCF-7 or MDA-MB-68 cancer cells. It inhibits tumor angiogenesis in all of the formed tumors. The inhibition is correlated with the expression of neuropilins of the tumors cells. PMID: 18818766

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed